A randomized trial of cisplatin versus cisplatin plus methotrexate in advanced cancer of the urothelial tract

B. L. Hillcoat, D. Raghavan, J. Matthews, R. Kefford, K. Yuen, R. Woods, I. Olver, J. Bishop, B. Pearson, G. Coorey, J. Levi, R. L. Abbott, R. Aroney, P. G. Gill, R. McLennan

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

One hundred eight patients with recurrent or metastatic transitional cell carcinoma of the urothelial tract were randomized to receive cisplatin (C) 80 mg/m2 on day 1 every 4 weeks, or methotrexate (M) 50 mg/m2 on days 1 and 15 plus C 80 mg/m2 on day 2 every 4 weeks (C + M). Fifty-three eligible patients were randomized to C + M and 55 to C. In the C + M arm 45% of patients responded (complete response [CR], 9%) and 31% (CR, 9%) in the C arm (P = 18). In the C arm, 20 patients responded, and four with progressive disease (PD) and one with a previous partial response (PR) showed no change. The median survival was 8.7 months (C = M arm) and 7.2 months (C arm), P = .7. Relapse-free survival was not significantly different, but C + M was associated with a significantly increased time to disease progression (median, 5.0 months, v 2.8 months for C arm). The response of untreated patients (37%) was not different from those with prior treatment (39%). On the C + M arm, 92% of patients and 96% of patients on the C arm received 85% or more of the scheduled C dose. Significantly more grade 3 or 4 hematological toxicity (27% v 2%; P = .01) and mucositis (20% v 0%; P = .0005) occurred in patients on the C + M arm. Although the initial response rates seen on the combination arm look superior, and the time to disease progression is increased, these effects have not translated into a clinically important increase in the duration of survival and were associated with increased toxicity.

Original languageEnglish
Pages (from-to)706-709
Number of pages4
JournalJournal of Clinical Oncology
Volume7
Issue number6
Publication statusPublished - 1989
Externally publishedYes

Fingerprint Dive into the research topics of 'A randomized trial of cisplatin versus cisplatin plus methotrexate in advanced cancer of the urothelial tract'. Together they form a unique fingerprint.

  • Cite this

    Hillcoat, B. L., Raghavan, D., Matthews, J., Kefford, R., Yuen, K., Woods, R., ... McLennan, R. (1989). A randomized trial of cisplatin versus cisplatin plus methotrexate in advanced cancer of the urothelial tract. Journal of Clinical Oncology, 7(6), 706-709.